Hydroxylapatite-collagen hybrid scaffold induces human adipose-derived mesenchymal stem cells to osteogenic differentiation in vitro and bone regrowth in patients.
Elisa MazzoniAntonio D'AgostinoMaria Rosa IaquintaIlaria BononiLorenzo TrevisiolJohn Charles RotondoSimone PatergnaniCarlotta GiorgiMichael J GunsonG William ArnettPier Francesco NociniMauro TognonFernanda MartiniPublished in: Stem cells translational medicine (2019)
Tissue engineering-based bone graft is an emerging viable treatment modality to repair and regenerate tissues damaged as a result of diseases or injuries. The structure and composition of scaffolds should modulate the classical osteogenic pathways in human stem cells. The osteoinductivity properties of the hydroxylapatite-collagen hybrid scaffold named Coll/Pro Osteon 200 were investigated in an in vitro model of human adipose mesenchymal stem cells (hASCs), whereas the clinical evaluation was carried out in maxillofacial patients. Differentially expressed genes (DEGs) induced by the scaffold were analyzed using the Osteogenesis RT2 PCR Array. The osteoinductivity potential of the scaffold was also investigated by studying the alkaline phosphatase (ALP) activity, matrix mineralization, osteocalcin (OCN), and CLEC3B expression protein. Fifty patients who underwent zygomatic augmentation and bimaxillary osteotomy were evaluated clinically, radiologically, and histologically during a 3-year follow-up. Among DEGs, osteogenesis-related genes, including BMP1/2, ALP, BGLAP, SP7, RUNX2, SPP1, and EGFR, which play important roles in osteogenesis, were found to be upregulated. The genes to cartilage condensation SOX9, BMPR1B, and osteoclast cells TNFSF11 were detected upregulated at every time point of the investigation. This scaffold has a high osteoinductivity revealed by the matrix mineralization, ALP activity, OCN, and CLEC3B expression proteins. Clinical evaluation evidences that the biomaterial promotes bone regrowth. Histological results of biopsy specimens from patients showed prominent ossification. Experimental data using the Coll/Pro Osteon 200 indicate that clinical evaluation of bone regrowth in patients, after scaffold implantation, was supported by DEGs implicated in skeletal development as shown in "in vitro" experiments with hASCs.
Keyphrases
- tissue engineering
- end stage renal disease
- stem cells
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- type diabetes
- bone marrow
- gene expression
- poor prognosis
- machine learning
- clinical evaluation
- metabolic syndrome
- tyrosine kinase
- oxidative stress
- mass spectrometry
- total knee arthroplasty
- ultrasound guided
- skeletal muscle
- insulin resistance
- cell death
- epidermal growth factor receptor
- soft tissue
- body composition
- induced apoptosis
- bone regeneration
- patient reported
- risk assessment
- electronic health record
- induced pluripotent stem cells
- atomic force microscopy
- single cell